Each business day, TheStreet.com Ratings TheStreet.com Ratings compiles a list of the top five stocks in one of five categories -- fast-growth, all-around value, large-cap, mid-cap and small-cap -- based on data from the close of the previous trading session. Today we focus on mid-caps.

These are stocks of companies that have market capitalizations of between $500 million and $10 billion that rank near the top of all stocks rated by our proprietary quantitative model, which looks at more than 60 factors.

The stocks must also be followed by at least one financial analyst who posts estimates on the Institutional Brokers' Estimate System. They are ordered by their potential to appreciate.

Note that no provision is made for off-balance-sheet assets such as unrealized appreciation/depreciation of investments, market value of real estate or contingent liabilities that might affect book value. This could be material for some companies with large underfunded pension plans.

DeVry ( DV) is an international higher education company that operates DeVry University, Ross University, Chamberlin College of Nursing and Becker Professional Review. The company has been rated a buy since January 2007. DeVry's strengths can be seen in a variety of areas, such as its impressive record of earnings-per-share growth, robust revenue growth, return on equity, and largely solid financial position. Solid stock price performance also contributes to the buy rating.

The company announced on Jan. 27 that its revenues rose 35% year over year in the second quarter of fiscal 2009, helped by increased revenue across segments and the acquisition of U.S. Education, which is the parent company of Apollo College and Western Career College. Revenue growth appears to have trickled down to the bottom line, as DeVry reported EPS improvement of 20.4%. Higher enrollment numbers also helped boost earnings. Net income also increased, rising to $42.9 million from $35.8 million in the second quarter of fiscal 2008. Return on equity, which improved slightly when compared to the same quarter a year ago, can be seen as a modest strength for the organization. In addition, a debt-to-equity ratio of 0.18 indicates that DeVry has successfully managed its debt levels.

Management was pleased not only with DeVry's financial results in the second quarter, but also with the employment rate of its graduates. Management stated that it was remarkable in the current job market to see 92% of recent graduates employed within six months of graduation. The company continues with a conservative capital structure that it feels is appropriate to the current economic climate, although it does continue to invest in growth opportunities. Looking ahead, DeVry expects its full year 2009 capital expenditure to be in the range of $65.00 million to $70 million. Although the company shows low profit margins, we feel that the strengths detailed above outweigh any weaknesses at this time.

Landauer ( LDR) offers personnel radiation monitoring to measure the dosages of x-rays, gamma radiation, and other penetrating ionizing radiation to which a person has been exposed. The company's services are primarily used by hospitals, medical and dental offices, university and national laboratories, nuclear power plants, and other industries in which employees may be threatened by radiation exposure. Our buy rating for Landauer has not changed since November 2001. The rating is supported by the company's revenue growth, increases in net income and earnings per share (EPS), notable return on equity, and expanding profit margins.

For the first quarter of fiscal 2009, Landauer reported that its revenue increased slightly, rising 2.9% year over year. This appears to have trickled down to the company's bottom line, as Landauer's EPS improved 15.8% when compared to the same quarter a year ago. Net income also increased for the fourth quarter, rising 16.4% from $5.3 million to $6.1 million. Return on equity improved slightly over the past year, improving from 32.6% to 33.6%, while a net profit margin of 27.4% significantly outperformed against the rest of the Health Care Providers and Services industry.

Management announced that it was pleased with its results for the first quarter and that it believes the company to be well-positioned for further success in the future despite challenging economic conditions. Looking ahead, the company anticipates net income growth in the range of 6% to 8% for full year fiscal 2009, along with aggregate revenue growth in the range of 3% to 5%. While we feel that Landauer's stock is currently trading at a premium valuation, we believe the strengths detailed above justify the higher price at this time.

ManTech International ( MANT - Get Report) provides technologies and solutions for mission-critical national security programs for the intelligence community, the space community, and various departments and agencies of the U.S. federal government. ManTech has been rated a buy since March 2005. Our rating is based on strengths such as the company's robust revenue growth, largely solid financial position, and record of EPS growth.

For the third quarter of fiscal 2008, revenue rose by 26.8% year over year. This increase was primarily the result of a business strategy focused on high-end defense and intelligence markets supporting U.S. national security. Revenue growth appears to have helped boost earnings per share, which improved 31.4% when compared to the same quarter a year ago. The EPS increase from 51 cents to 67 cents represents the continuation of a pattern of positive EPS growth demonstrated by ManTech over the past two years, a trend which we feel should continue. Net income also increased in the third quarter, rising from $17.5 million in the third quarter of fiscal 2007 to $23.9 million in the most recent quarter. ManTech's very low debt-to-equity ratio of 0.007 and quick ratio of 1.4 illustrate the company's successful management of debt levels and ability to avoid short-term cash problems.

Management announced it was pleased with the third quarter results, as strong performance and excellent cash flow helped provide necessary flexibility in a challenging economic environment. Based on strong business momentum in its national security and defense business, the company set EPS guidance at 67 cents to 70 cents for the fourth quarter and $2.53 to $2.56 for full-year fiscal 2008. These ranges represent 10% to 15% growth over the fourth quarter of fiscal 2007 and 30% to 31% growth over full-year fiscal 2007. The company currently shows low profit margins, but we feel that the strengths detailed above outweigh any potential weakness.

Haemonetics ( HAE - Get Report) is a global leader in blood processing technology, designing, manufacturing and marketing automated blood processing systems and single use consumables for blood donors and surgical patients. Our buy rating for Haemonetics has been in place since February 2004, based on such strengths as the company's robust revenue growth, largely solid financial position, improvement in net income and EPS and solid stock price performance.

For the third quarter of fiscal 2009, the company reported on Feb. 2 that its revenue rose 15.5% year over year, with double-digit growth recorded across all geographies. This improvement slightly outpaced the industry average of 13.6%. It also appears to have trickled down to the company's bottom line, as EPS increased 14.8% when compared to the same quarter a year ago. Net income grew 13.1%, rising from $14.3 million to $16.2 million. Haemonetics has a very low debt-to-equity ratio of 0.02, implying that it has successfully managed its debt levels. In addition, a quick ratio of 2.9 indicates that the company has the ability to cover its short-term cash needs.

Due to stronger-than-planned sales of plasma disposables, blood bank disposables, and equipment and the strong third quarter revenue results from all geographies, Haemonetics raised its full year revenue guidance. The company now anticipates revenue growth of 15% to 16%, up from previously announced expectations for 12% to 14% full year revenue growth. The company shows somewhat disappointing return on equity, but we feel that the strengths detailed above outweigh any potential weakness at this time.

New Jersey Resources ( NJR - Get Report) is an energy services holding company that provides retail and wholesale energy services to customers in New Jersey, other states from the Gulf Coast to New England, and Canada. Our buy rating for New Jersey Resources Corporation has been in place since September 2002. This rating is supported by the company's healthy revenue growth, solid stock price performance, compelling net income growth, notable return on equity, and good cash flow from operations.

New Jersey Resources reported results for its first quarter of fiscal 2009 on Feb. 4. These results will be fully updated in our model shortly, but bear in mind that our current rating is based on the company's fourth quarter of fiscal 2008. The company reported fourth quarter revenue growth of 40.1% year over year, which outpaced the industry average of 22.6%. Revenue growth appears to have helped boost EPS, which rose significantly from a loss of $0.91 per share in the fourth quarter of fiscal 2007 to a profit of $1.86 in the most recent quarter. Net income surged 305.1% when compared to the same quarter a year ago. In addition, the company announced that its Board of Directors recently approved a 10.7% dividend increase, bringing the quarterly dividend rate to 31 cents per share. The company has paid quarterly dividends continuously since it began in 1952.

Looking ahead to fiscal 2009, New Jersey Resources' guidance at the end of the fourth quarter called for net financial earnings in the range of $2.30 to $2.40 per basic share. Approximately 30% to 40% of those earnings are expected to come from the company's wholesale energy services subsidiary, NJR Energy Services. The company shows relatively poor debt management on most measures we evaluated, but we feel that its strengths outweigh any potential weakness at this time. Strong earnings growth has helped the stock price rise over the past year, and the stock should see more upside potential unless a broad bear market prevails.

Our quantitative rating, which can be viewed for any stock through our stock screener stock rating screener, is based on a variety of historical fundamental and pricing data and represents our opinion of a stock's risk-adjusted performance relative to other stocks.

However, the rating does not incorporate all of the factors that can alter a stock's performance. For example, it doesn't always factor in recent corporate or industry events that could affect the stock price, nor does it include recent technology developments and competitive dynamics that may affect the company.

For those reasons, we believe a rating alone cannot tell the whole story and should be part of an investor's overall research.